UY32213A - Anticuerpos humanos de alta afinidad para el receptor il-4 humano - Google Patents

Anticuerpos humanos de alta afinidad para el receptor il-4 humano

Info

Publication number
UY32213A
UY32213A UY0001032213A UY32213A UY32213A UY 32213 A UY32213 A UY 32213A UY 0001032213 A UY0001032213 A UY 0001032213A UY 32213 A UY32213 A UY 32213A UY 32213 A UY32213 A UY 32213A
Authority
UY
Uruguay
Prior art keywords
human
high affinity
receiver
hil
antibodies
Prior art date
Application number
UY0001032213A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas J Papadopoulos
Joel H Martin
Tammy T Huang
Jeanette L Fairhurst
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY32213A publication Critical patent/UY32213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
UY0001032213A 2008-10-29 2009-10-29 Anticuerpos humanos de alta afinidad para el receptor il-4 humano UY32213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor

Publications (1)

Publication Number Publication Date
UY32213A true UY32213A (es) 2010-05-31

Family

ID=41600767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032213A UY32213A (es) 2008-10-29 2009-10-29 Anticuerpos humanos de alta afinidad para el receptor il-4 humano

Country Status (47)

Country Link
US (7) US7608693B2 (en:Method)
EP (7) EP4345111A3 (en:Method)
JP (8) JP5291802B2 (en:Method)
KR (1) KR101599706B1 (en:Method)
CN (3) CN102197052B (en:Method)
AR (1) AR073978A1 (en:Method)
AU (1) AU2009311496B9 (en:Method)
BR (1) BRPI0919853B8 (en:Method)
CA (1) CA2737044C (en:Method)
CL (1) CL2009002004A1 (en:Method)
CO (1) CO6362024A2 (en:Method)
CR (1) CR20110148A (en:Method)
CY (3) CY1114123T1 (en:Method)
DK (3) DK3715372T5 (en:Method)
EC (1) ECSP11011010A (en:Method)
ES (4) ES2404206T3 (en:Method)
FI (1) FI3715372T3 (en:Method)
FR (1) FR18C1011I2 (en:Method)
HN (1) HN2011001210A (en:Method)
HR (3) HRP20130467T1 (en:Method)
HU (3) HUS1800014I1 (en:Method)
IL (1) IL211726A (en:Method)
JO (1) JO2865B1 (en:Method)
LT (3) LT3064511T (en:Method)
LU (1) LUC00059I2 (en:Method)
MA (1) MA32802B1 (en:Method)
MX (3) MX356882B (en:Method)
MY (1) MY152448A (en:Method)
NI (1) NI201100064A (en:Method)
NL (1) NL300922I2 (en:Method)
NO (2) NO2018009I2 (en:Method)
NZ (2) NZ596093A (en:Method)
PA (1) PA8847001A1 (en:Method)
PE (1) PE20100738A1 (en:Method)
PH (1) PH12014500462A1 (en:Method)
PL (4) PL3351560T3 (en:Method)
PT (4) PT2356151E (en:Method)
RS (3) RS65385B1 (en:Method)
RU (2) RU2539774C3 (en:Method)
SI (3) SI3064511T1 (en:Method)
SM (2) SMT201800362T1 (en:Method)
SV (1) SV2011003880A (en:Method)
TW (3) TW201919700A (en:Method)
UA (1) UA102122C2 (en:Method)
UY (1) UY32213A (en:Method)
WO (1) WO2010053751A1 (en:Method)
ZA (1) ZA201101867B (en:Method)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741783A4 (en) * 2004-04-27 2009-05-27 Chemo Sero Therapeut Res Inst HUMAN ANTIAMYLOID BETA PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF
RS53340B (sr) * 2006-10-02 2014-10-31 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta za humani il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
EP3354280B1 (en) 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
BR112013018877A2 (pt) 2011-01-28 2016-10-04 Sanofi Sa composições farmacêuticas que compreendem anticorpos humanos para pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
LT3572517T (lt) 2011-08-05 2021-04-26 Regeneron Pharmaceuticals, Inc. Humanizuotos universalios lengvosios grandinės pelės
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
PT2796550T (pt) * 2011-12-22 2018-04-18 Astellas Pharma Inc Novo anticorpo ctgf anti-humano
DK2825037T3 (da) 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
SMT201800229T1 (it) 2012-03-16 2018-07-17 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
KR102307248B1 (ko) * 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
TWI721272B (zh) * 2012-08-21 2021-03-11 法商賽諾菲生物技術公司 投與il-4r拮抗劑以治療或預防氣喘之方法
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
PT2892927T (pt) * 2012-09-07 2018-08-02 Regeneron Pharma Métodos para tratamento da dermatite atópica por administração de um antagonista de il-4r
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN105517570B (zh) * 2013-06-21 2020-04-07 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
DK3010539T3 (da) * 2013-06-21 2019-10-21 Sanofi Biotechnology Fremgangsmåder til behandling af nasal polyposis ved administration af en il-4r-antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
DE112014005747T5 (de) * 2013-12-17 2016-10-06 Kymab Limited Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
ES2973858T3 (es) 2014-02-28 2024-06-24 Regeneron Pharma Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
NO2785538T3 (en:Method) 2014-05-07 2018-08-04
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP6938383B2 (ja) * 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
ES3052976T3 (en) 2015-08-18 2026-01-16 Regeneron Pharma Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
MX2018009990A (es) 2016-02-19 2018-12-17 Regeneron Pharma Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
CA3035202A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
CN110914293B (zh) 2017-07-06 2024-08-13 里珍纳龙药品有限公司 用于制备糖蛋白的细胞培养工艺
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CA3084059A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
CN110105451B (zh) * 2018-02-01 2020-12-18 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20260004591A (ko) 2018-02-28 2026-01-08 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
IL277264B2 (en) 2018-03-19 2024-03-01 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP3768317A4 (en) 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
AU2019270940A1 (en) 2018-05-13 2020-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
CA3104873A1 (en) 2018-07-10 2020-01-16 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
JP7405831B2 (ja) * 2018-08-24 2023-12-26 ジエンス ヘンルイ メデイシンカンパニー リミテッド ヒトｉｌ－４ｒ結合抗体、その抗原結合フラグメント、およびそれらの医学的使用
AU2019329686A1 (en) 2018-08-27 2020-12-03 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
AU2019333047A1 (en) 2018-08-30 2020-12-03 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
KR102330596B1 (ko) * 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
US11579150B2 (en) 2019-01-16 2023-02-14 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
JP7548924B2 (ja) 2019-03-06 2024-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
CN112010977B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2022543815A (ja) 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
CN114667450B (zh) 2019-09-24 2025-05-02 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111825766B (zh) 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
BR112022009974A2 (pt) 2019-11-25 2022-08-16 Regeneron Pharma Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN115461818A (zh) 2019-12-09 2022-12-09 赛诺菲生物技术公司 治疗数字鉴定的il-4/il-13相关障碍的方法
AU2020407853A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
KR20220143882A (ko) 2020-02-21 2022-10-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il-4r 항체를 함유하는 약학적 조성물 및 이의 용도
CN119708230A (zh) * 2020-02-27 2025-03-28 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
CN115768516A (zh) 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
TW202432837A (zh) 2020-08-31 2024-08-16 美商再生元醫藥公司 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
TW202231663A (zh) * 2020-12-22 2022-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
BR112023017442A2 (pt) 2021-03-03 2023-09-26 Regeneron Pharma Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
KR20240015646A (ko) 2021-06-01 2024-02-05 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
AU2022316939A1 (en) 2021-07-26 2024-03-07 Regeneron Pharmaceuticals, Inc. Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
AU2022326849A1 (en) 2021-08-10 2024-03-21 Kymab Limited Treatment of atopic dermatitis
US20230167171A1 (en) 2021-08-23 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL310427A (en) * 2021-08-26 2024-03-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pharmaceutical composition of anti-il4r antibody and use thereof
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en) * 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
EP4409037A1 (en) 2021-09-30 2024-08-07 Regeneron Pharmaceuticals, Inc. Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
IL311245A (en) 2021-10-07 2024-05-01 Regeneron Pharma Systems and methods for pH modeling and control
MX2024004762A (es) 2021-10-20 2024-05-08 Sanofi Biotechnology Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
EP4423018A1 (en) 2021-10-26 2024-09-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023086887A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
JP2024542194A (ja) 2021-11-18 2024-11-13 ツイスト バイオサイエンス コーポレーション Ｄｉｃｋｋｏｐｆ－１バリアント抗体及び使用方法
US20230272062A1 (en) 2021-11-30 2023-08-31 Regeneron Pharmaceuticals, Inc. Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent
AU2022425608A1 (en) 2021-12-30 2024-08-15 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
MX2024009080A (es) 2022-01-29 2024-07-30 Shanghai Shengdi Pharmaceutical Co Ltd Conjugado farmacologico de glucocorticoide.
US20230348532A1 (en) 2022-03-02 2023-11-02 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
AU2023233590A1 (en) 2022-03-18 2024-10-17 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
JP2025522904A (ja) 2022-07-08 2025-07-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによる小児好酸球性食道炎の処置方法
EP4580659A1 (en) 2022-08-29 2025-07-09 Sanofi Biotechnology Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
US20240141051A1 (en) 2022-11-01 2024-05-02 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
CN120530132A (zh) * 2023-02-17 2025-08-22 顶峰疗法股份有限公司 结合白介素4受体α的抗体和使用方法
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024197119A1 (en) 2023-03-22 2024-09-26 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
WO2024199665A1 (en) 2023-03-30 2024-10-03 Sandoz Ag Stable composition comprising a high protein concentration
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
KR20240170605A (ko) * 2023-05-23 2024-12-04 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이를 포함하는 비강 분무 제형
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025117516A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating cd20-related disorders
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
WO2025166234A1 (en) * 2024-01-31 2025-08-07 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 4 receptor alpha
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
US20250388685A1 (en) 2024-04-15 2025-12-25 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
US20260008857A1 (en) * 2024-06-13 2026-01-08 Flagship Pioneering Innovations Vi, Llc Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra)
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0668774A1 (en) * 1991-05-03 1995-08-30 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
US5863537A (en) * 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE372764T1 (de) 2000-07-26 2007-09-15 Hououdou Co Ltd Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR20030065539A (ko) 2000-12-22 2003-08-06 소시에떼 데 프로듀이 네슬레 소시에떼아노님 내성 유도
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
US20050074462A1 (en) 2001-05-23 2005-04-07 Duotol Ab Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
EP2298717B1 (en) 2001-11-30 2015-10-28 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
DE60328195D1 (de) 2002-03-29 2009-08-13 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2514840C (en) 2003-02-01 2017-11-07 Tanox, Inc. High affinity, anti-human ige antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US20050112694A1 (en) 2003-11-07 2005-05-26 Carter Paul J. Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009523460A (ja) 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
RS53340B (sr) 2006-10-02 2014-10-31 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta za humani il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
AU2008339576B2 (en) 2007-12-21 2014-05-22 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20120004205A1 (en) 2008-12-01 2012-01-05 Cincinnati Children's Hospital Medical Center Il-13 induced gene signature for eosinophilic esophagitis
WO2010120524A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
EP2475382B1 (en) 2009-09-07 2015-01-14 DBV Technologies Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
EP3354280B1 (en) * 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
WO2013051928A1 (en) 2011-10-06 2013-04-11 N.V. Nutricia Treatment of eosinophilic esophagitis
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
KR102307248B1 (ko) * 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN105517570B (zh) 2013-06-21 2020-04-07 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
ES2973858T3 (es) 2014-02-28 2024-06-24 Regeneron Pharma Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
AU2015346150B2 (en) * 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
MX2018009990A (es) 2016-02-19 2018-12-17 Regeneron Pharma Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA3035202A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
AU2019270940A1 (en) 2018-05-13 2020-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
JP2022543815A (ja) 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN115461818A (zh) 2019-12-09 2022-12-09 赛诺菲生物技术公司 治疗数字鉴定的il-4/il-13相关障碍的方法
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN115768516A (zh) 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Also Published As

Publication number Publication date
SV2011003880A (es) 2011-08-15
JP5844772B2 (ja) 2016-01-20
AR073978A1 (es) 2010-12-15
NI201100064A (es) 2011-11-02
SMT201800362T1 (it) 2018-09-13
LTPA2018002I1 (lt) 2018-02-12
PE20100738A1 (es) 2010-11-03
NO2023019I1 (no) 2023-05-02
PA8847001A1 (es) 2010-05-26
NZ596093A (en) 2012-11-30
CL2009002004A1 (es) 2010-03-05
JP5291802B2 (ja) 2013-09-18
US20090074793A1 (en) 2009-03-19
ES2975006T3 (es) 2024-07-02
EP3715372B1 (en) 2024-01-24
EP3064511B1 (en) 2018-04-18
JP2020007378A (ja) 2020-01-16
ECSP11011010A (es) 2011-06-30
JP2019055963A (ja) 2019-04-11
CN106267190A (zh) 2017-01-04
SI3715372T1 (sl) 2024-05-31
TWI538686B (zh) 2016-06-21
TW201919700A (zh) 2019-06-01
US8075887B2 (en) 2011-12-13
FR18C1011I2 (fr) 2020-03-06
TW201029664A (en) 2010-08-16
PL2356151T3 (pl) 2013-08-30
FR18C1011I1 (en:Method) 2018-04-27
WO2010053751A1 (en) 2010-05-14
EP3064511A1 (en) 2016-09-07
CY1122092T1 (el) 2020-07-31
LTC2356151I2 (lt) 2019-04-10
TW201615216A (zh) 2016-05-01
BRPI0919853A2 (pt) 2016-03-15
RS65385B1 (sr) 2024-04-30
HUE039212T2 (hu) 2018-12-28
ES2675917T3 (es) 2018-07-13
JP6449125B2 (ja) 2019-01-09
EP4345111A2 (en) 2024-04-03
SI3064511T1 (en) 2018-08-31
MX388436B (es) 2025-03-20
MY152448A (en) 2014-09-30
RS57522B1 (sr) 2018-10-31
US20100047254A1 (en) 2010-02-25
US12162943B2 (en) 2024-12-10
RU2011120194A (ru) 2012-12-10
MX356882B (es) 2018-06-19
HN2011001210A (es) 2013-10-22
JP2024040526A (ja) 2024-03-25
KR101599706B1 (ko) 2016-03-04
US8337839B2 (en) 2012-12-25
US20180179288A1 (en) 2018-06-28
CA2737044C (en) 2017-02-28
CY1114123T1 (el) 2016-07-27
RS52782B (sr) 2013-10-31
EP2636685A1 (en) 2013-09-11
AU2009311496B2 (en) 2014-05-29
ES2404206T3 (es) 2013-05-24
DK3715372T3 (da) 2024-03-11
LUC00059I2 (en:Method) 2018-03-28
RU2663106C2 (ru) 2018-08-01
BRPI0919853B8 (pt) 2021-05-25
NO2018009I2 (no) 2019-01-30
EP2356151A1 (en) 2011-08-17
UA102122C2 (ru) 2013-06-10
AU2009311496B9 (en) 2014-10-30
DK2356151T3 (da) 2013-06-17
NO2018009I1 (no) 2018-03-06
LUC00059I1 (en:Method) 2018-01-03
DK3064511T3 (en) 2018-07-16
HUE066473T2 (hu) 2024-08-28
PL3351560T3 (pl) 2020-09-21
PT3351560T (pt) 2020-05-11
CN102197052A (zh) 2011-09-21
PT2356151E (pt) 2013-05-07
IL211726A0 (en) 2011-06-30
JP2012507294A (ja) 2012-03-29
HRP20181148T1 (hr) 2018-09-21
HRP20130467T1 (en) 2013-06-30
US7608693B2 (en) 2009-10-27
AU2009311496A1 (en) 2010-05-14
LT3715372T (lt) 2024-03-25
HRP20240492T1 (hr) 2024-07-05
EP4345111A3 (en) 2024-05-22
DK3715372T5 (da) 2024-08-26
EP2356151B1 (en) 2013-04-10
EP3715372A1 (en) 2020-09-30
BRPI0919853B1 (pt) 2020-10-27
HK1250733A1 (en) 2019-01-11
CN102197052B (zh) 2014-02-12
US20130078675A1 (en) 2013-03-28
US8735095B2 (en) 2014-05-27
EP3351560A1 (en) 2018-07-25
IL211726A (en) 2015-10-29
US20210163611A1 (en) 2021-06-03
JP6608505B2 (ja) 2019-11-20
CY2018003I2 (el) 2018-09-05
CN103739711A (zh) 2014-04-23
PL3715372T3 (pl) 2024-06-24
FI3715372T3 (fi) 2024-03-18
SMT201300074B (it) 2013-09-06
JP2022160404A (ja) 2022-10-19
CA2737044A1 (en) 2010-05-14
PH12014500462A1 (en) 2015-06-01
JP2013223495A (ja) 2013-10-31
TWI658833B (zh) 2019-05-11
MA32802B1 (fr) 2011-11-01
PT3064511T (pt) 2018-07-17
ES2802241T3 (es) 2021-01-18
JP6843208B2 (ja) 2021-03-17
JP2021087440A (ja) 2021-06-10
NZ591922A (en) 2012-03-30
JP7442581B2 (ja) 2024-03-04
CN103739711B (zh) 2016-09-14
PT3715372T (pt) 2024-03-14
US20120052072A1 (en) 2012-03-01
LT3064511T (lt) 2018-07-10
MX2011003346A (es) 2011-04-21
KR20110074980A (ko) 2011-07-05
NL300922I2 (nl) 2019-01-15
ZA201101867B (en) 2012-08-29
CY2018003I1 (el) 2018-09-05
SI2356151T1 (sl) 2013-07-31
RU2539774C3 (ru) 2020-11-06
RU2014147773A (ru) 2016-06-20
CR20110148A (es) 2011-04-27
CN106267190B (zh) 2021-01-26
HUS1800014I1 (hu) 2018-03-28
JP7100731B2 (ja) 2022-07-13
EP2511300A2 (en) 2012-10-17
RU2539774C2 (ru) 2015-01-27
PL3064511T3 (pl) 2018-09-28
JP2016041069A (ja) 2016-03-31
US20140271681A1 (en) 2014-09-18
EP3351560B1 (en) 2020-04-22
EP2511300A3 (en) 2012-11-07
CO6362024A2 (es) 2012-01-20
HK1159136A1 (en) 2012-07-27
JO2865B1 (en) 2015-03-15

Similar Documents

Publication Publication Date Title
UY32213A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
NI200900041A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
UY32665A (es) Proteinas de union al antigeno
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
AR081750A1 (es) Anticuerpos anti-cd40
MX2016005687A (es) Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CL2011000269A1 (es) Anticuerpo o fragmento del mismo que se une a cd127; y metodo de tratamiento de enfermedad autoinmune o un trastorno inflamatorio en humanos, que comprende administrar un antagonista de al menos una de la expansion de th17 mediada por el receptor de il-7 y la supervivencia de th17 mediada por el receptor de il-7.
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
SV2011003891A (es) Antagonistas de los receptores tipo toll 3
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
AR066306A1 (es) Conjunto de partes para el tratamiento del cancer o enfermedades infecciosas. composicion farmaceutica- usos
AR073140A1 (es) Anticuerpos anti-il-23r disenados
CO6390112A2 (es) Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
TN2011000133A1 (en) High affinity human antibodies to human il-4 receptor
GT200900278A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
HN2009000575A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127